DANONE (BSN.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:BSN - FR0000120644 - Common Stock
75.46 EUR
-1.02 (-1.33%)
Overall BSN gets a fundamental rating of 5 out of 10. We evaluated BSN against 63 industry peers in the Food Products industry. BSN has an excellent profitability rating, but there are some minor concerns on its financial health. While showing a medium growth rate, BSN is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
- BSN had positive earnings in the past year.
- In the past year BSN had a positive cash flow from operations.
- In the past 5 years BSN has always been profitable.
- BSN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of 4.20%, BSN is in the better half of the industry, outperforming 63.49% of the companies in the same industry.
- BSN has a Return On Equity of 11.59%. This is in the better half of the industry: BSN outperforms 68.25% of its industry peers.
- With a decent Return On Invested Capital value of 6.83%, BSN is doing good in the industry, outperforming 66.67% of the companies in the same industry.
- BSN had an Average Return On Invested Capital over the past 3 years of 6.38%. This is in line with the industry average of 6.78%.
- The 3 year average ROIC (6.38%) for BSN is below the current ROIC(6.83%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.2% | ||
| ROE | 11.59% | ||
| ROIC | 6.83% |
ROA(3y)2.83%
ROA(5y)3.44%
ROE(3y)7.34%
ROE(5y)9%
ROIC(3y)6.38%
ROIC(5y)6.21%
1.3 Margins
- BSN has a better Profit Margin (6.72%) than 73.02% of its industry peers.
- In the last couple of years the Profit Margin of BSN has remained more or less at the same level.
- BSN has a Operating Margin of 13.25%. This is amongst the best in the industry. BSN outperforms 80.95% of its industry peers.
- In the last couple of years the Operating Margin of BSN has declined.
- BSN's Gross Margin of 50.47% is amongst the best of the industry. BSN outperforms 84.13% of its industry peers.
- BSN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.25% | ||
| PM (TTM) | 6.72% | ||
| GM | 50.47% |
OM growth 3Y-1.81%
OM growth 5Y-3.08%
PM growth 3Y-1.94%
PM growth 5Y-0.54%
GM growth 3Y1.56%
GM growth 5Y0.26%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so BSN is still creating some value.
- BSN has more shares outstanding than it did 1 year ago.
- BSN has less shares outstanding than it did 5 years ago.
- The debt/assets ratio for BSN has been reduced compared to a year ago.
2.2 Solvency
- BSN has an Altman-Z score of 2.53. This is not the best score and indicates that BSN is in the grey zone with still only limited risk for bankruptcy at the moment.
- The Altman-Z score of BSN (2.53) is better than 63.49% of its industry peers.
- BSN has a debt to FCF ratio of 5.07. This is a neutral value as BSN would need 5.07 years to pay back of all of its debts.
- BSN has a Debt to FCF ratio of 5.07. This is in the better half of the industry: BSN outperforms 73.02% of its industry peers.
- BSN has a Debt/Equity ratio of 0.83. This is a neutral value indicating BSN is somewhat dependend on debt financing.
- With a Debt to Equity ratio value of 0.83, BSN is not doing good in the industry: 69.84% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.83 | ||
| Debt/FCF | 5.07 | ||
| Altman-Z | 2.53 |
ROIC/WACC1.06
WACC6.42%
2.3 Liquidity
- BSN has a Current Ratio of 0.95. This is a bad value and indicates that BSN is not financially healthy enough and could expect problems in meeting its short term obligations.
- With a Current ratio value of 0.95, BSN is not doing good in the industry: 69.84% of the companies in the same industry are doing better.
- BSN has a Quick Ratio of 0.95. This is a bad value and indicates that BSN is not financially healthy enough and could expect problems in meeting its short term obligations.
- BSN's Quick ratio of 0.78 is in line compared to the rest of the industry. BSN outperforms 46.03% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.95 | ||
| Quick Ratio | 0.78 |
3. Growth
3.1 Past
- BSN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.47%.
- The Earnings Per Share has been decreasing by -1.17% on average over the past years.
- BSN shows a small growth in Revenue. In the last year, the Revenue has grown by 0.54%.
- Measured over the past years, BSN shows a small growth in Revenue. The Revenue has been growing by 1.60% on average per year.
EPS 1Y (TTM)4.47%
EPS 3Y3.12%
EPS 5Y-1.17%
EPS Q2Q%6.11%
Revenue 1Y (TTM)0.54%
Revenue growth 3Y4.08%
Revenue growth 5Y1.6%
Sales Q2Q%-0.15%
3.2 Future
- Based on estimates for the next years, BSN will show a small growth in Earnings Per Share. The EPS will grow by 6.09% on average per year.
- Based on estimates for the next years, BSN will show a small growth in Revenue. The Revenue will grow by 2.86% on average per year.
EPS Next Y7.99%
EPS Next 2Y7.4%
EPS Next 3Y7.7%
EPS Next 5Y6.09%
Revenue Next Year0.7%
Revenue Next 2Y1.88%
Revenue Next 3Y2.56%
Revenue Next 5Y2.86%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 20.18 indicates a rather expensive valuation of BSN.
- The rest of the industry has a similar Price/Earnings ratio as BSN.
- BSN is valuated rather cheaply when we compare the Price/Earnings ratio to 27.47, which is the current average of the S&P500 Index.
- With a Price/Forward Earnings ratio of 18.02, BSN is valued on the expensive side.
- Based on the Price/Forward Earnings ratio, BSN is valued a bit more expensive than 60.32% of the companies in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 24.26. BSN is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.18 | ||
| Fwd PE | 18.02 |
4.2 Price Multiples
- BSN's Enterprise Value to EBITDA ratio is in line with the industry average.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of BSN is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 17.92 | ||
| EV/EBITDA | 10.98 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- BSN has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.52
PEG (5Y)N/A
EPS Next 2Y7.4%
EPS Next 3Y7.7%
5. Dividend
5.1 Amount
- BSN has a Yearly Dividend Yield of 2.82%.
- Compared to an average industry Dividend Yield of 2.42, BSN pays a bit more dividend than its industry peers.
- Compared to an average S&P500 Dividend Yield of 1.89, BSN pays a bit more dividend than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.82% |
5.2 History
- The dividend of BSN has a limited annual growth rate of 1.58%.
Dividend Growth(5Y)1.58%
Div Incr Years3
Div Non Decr Years4
5.3 Sustainability
- BSN pays out 74.99% of its income as dividend. This is not a sustainable payout ratio.
- The dividend of BSN is growing, but earnings are growing more, so the dividend growth is sustainable.
DP74.99%
EPS Next 2Y7.4%
EPS Next 3Y7.7%
FRA:BSN (1/16/2026, 7:00:00 PM)
75.46
-1.02 (-1.33%)
Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryFood Products
Earnings (Last)10-07 2025-10-07
Earnings (Next)02-20 2026-02-20/amc
Inst Owners54.21%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap51.42B
Revenue(TTM)27.36B
Net Income(TTM)1.84B
Analysts75.33
Price Target80.85 (7.14%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.82% |
Yearly Dividend2.1
Dividend Growth(5Y)1.58%
DP74.99%
Div Incr Years3
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.1%
PT rev (3m)2.78%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0.32%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.16%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.18 | ||
| Fwd PE | 18.02 | ||
| P/S | 1.88 | ||
| P/FCF | 17.92 | ||
| P/OCF | 13.37 | ||
| P/B | 3.24 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.98 |
EPS(TTM)3.74
EY4.96%
EPS(NY)4.19
Fwd EY5.55%
FCF(TTM)4.21
FCFY5.58%
OCF(TTM)5.64
OCFY7.48%
SpS40.15
BVpS23.28
TBVpS-9.5
PEG (NY)2.52
PEG (5Y)N/A
Graham Number44.26
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.2% | ||
| ROE | 11.59% | ||
| ROCE | 12.02% | ||
| ROIC | 6.83% | ||
| ROICexc | 8.36% | ||
| ROICexgc | 50.58% | ||
| OM | 13.25% | ||
| PM (TTM) | 6.72% | ||
| GM | 50.47% | ||
| FCFM | 10.49% |
ROA(3y)2.83%
ROA(5y)3.44%
ROE(3y)7.34%
ROE(5y)9%
ROIC(3y)6.38%
ROIC(5y)6.21%
ROICexc(3y)7.67%
ROICexc(5y)7.39%
ROICexgc(3y)52.44%
ROICexgc(5y)45.6%
ROCE(3y)10.98%
ROCE(5y)10.58%
ROICexgc growth 3Y19.7%
ROICexgc growth 5Y13.36%
ROICexc growth 3Y4.65%
ROICexc growth 5Y1.26%
OM growth 3Y-1.81%
OM growth 5Y-3.08%
PM growth 3Y-1.94%
PM growth 5Y-0.54%
GM growth 3Y1.56%
GM growth 5Y0.26%
F-Score8
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.83 | ||
| Debt/FCF | 5.07 | ||
| Debt/EBITDA | 2.71 | ||
| Cap/Depr | 77.72% | ||
| Cap/Sales | 3.57% | ||
| Interest Coverage | 23.53 | ||
| Cash Conversion | 78.8% | ||
| Profit Quality | 156.01% | ||
| Current Ratio | 0.95 | ||
| Quick Ratio | 0.78 | ||
| Altman-Z | 2.53 |
F-Score8
WACC6.42%
ROIC/WACC1.06
Cap/Depr(3y)59.49%
Cap/Depr(5y)65.43%
Cap/Sales(3y)3.2%
Cap/Sales(5y)3.59%
Profit Quality(3y)220.86%
Profit Quality(5y)178.79%
High Growth Momentum
Growth
EPS 1Y (TTM)4.47%
EPS 3Y3.12%
EPS 5Y-1.17%
EPS Q2Q%6.11%
EPS Next Y7.99%
EPS Next 2Y7.4%
EPS Next 3Y7.7%
EPS Next 5Y6.09%
Revenue 1Y (TTM)0.54%
Revenue growth 3Y4.08%
Revenue growth 5Y1.6%
Sales Q2Q%-0.15%
Revenue Next Year0.7%
Revenue Next 2Y1.88%
Revenue Next 3Y2.56%
Revenue Next 5Y2.86%
EBIT growth 1Y3.81%
EBIT growth 3Y2.2%
EBIT growth 5Y-1.53%
EBIT Next Year35.93%
EBIT Next 3Y14.73%
EBIT Next 5Y10.6%
FCF growth 1Y12.42%
FCF growth 3Y6.14%
FCF growth 5Y3.12%
OCF growth 1Y12.55%
OCF growth 3Y3.31%
OCF growth 5Y2.15%
DANONE / BSN.DE FAQ
What is the fundamental rating for BSN stock?
ChartMill assigns a fundamental rating of 5 / 10 to BSN.DE.
What is the valuation status for BSN stock?
ChartMill assigns a valuation rating of 3 / 10 to DANONE (BSN.DE). This can be considered as Overvalued.
How profitable is DANONE (BSN.DE) stock?
DANONE (BSN.DE) has a profitability rating of 7 / 10.
What is the earnings growth outlook for DANONE?
The Earnings per Share (EPS) of DANONE (BSN.DE) is expected to grow by 7.99% in the next year.
Is the dividend of DANONE sustainable?
The dividend rating of DANONE (BSN.DE) is 5 / 10 and the dividend payout ratio is 74.99%.